Get the Stockscreener App
0.80
23.08%
0.15
After Hours:
.76
-0.04
-5.00%
Glucotrack Inc stock is traded at $0.80, with a volume of 440.29K.
It is up +23.08% in the last 24 hours and down -48.39% over the past month.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
See More
Previous Close:
$0.65
Open:
$0.66
24h Volume:
440.29K
Relative Volume:
0.51
Market Cap:
$809.02K
Revenue:
-
Net Income/Loss:
$-19.39M
P/E Ratio:
-0.0423
EPS:
-18.9115
Net Cash Flow:
$-15.34M
1W Performance:
-23.08%
1M Performance:
-48.39%
6M Performance:
-87.46%
1Y Performance:
+255.56%
1-Day Range:
$0.62
$0.80
1-Week Range:
$0.619
$1.67
52-Week Range:
$0.0927
$15.90
Glucotrack Inc Stock (GCTK) Company Profile
Name
Glucotrack Inc
Sector
Industry
Phone
972 (8) 675-7878
Address
301 RT 17 NORTH, RUTHERFORD
Compare GCTK vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GCTK
Glucotrack Inc
|
0.80 | 657.33K | 0 | -19.39M | -15.34M | -18.91 |
ISRG
Intuitive Surgical Inc
|
464.45 | 163.73B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
156.34 | 44.73B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
75.51 | 36.73B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
44.00 | 36.12B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
222.85 | 32.70B | 5.40B | 1.49B | 1.78B | 10.12 |
Glucotrack Inc Stock (GCTK) Latest News
Glucotrack reports net loss of USD 19.4M in FY 2025 - Medical Buyer
Glucotrack, Inc. 2025 Annual Report – Implantable Continuous Blood Glucose Monitor Development, Regulatory Progress, and Risk Factors 66 - Minichart
GCTK: Improved net loss and cash position support 2026 clinical trial launch for implantable CBGM - tradingview.com
Glucotrack (GCTK) advances implantable CBGM but flags going concern risk - Stock Titan
GlucoTrack, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Glucotrack (NASDAQ: GCTK) trims 2025 loss and readies IDE for implantable CBGM trials - Stock Titan
Glucotrack, Inc. Announces IDE Filing Plans for Continuous Blood Glucose Monitoring Technology and Patents Issued by USPTO - Quiver Quantitative
Glucotrack’s 3-year glucose implant targets a U.S. human trial in 2026 - Stock Titan
GCTK stock is soaring pre-market today — what is fueling the surge? - MSN
Technical Analysis: What analysts say about GlucoTrack Inc stock2026 Analyst Calls & Low Drawdown Trading Techniques - baoquankhu1.vn
GlucoTrack Plummets 27%: Is This the Bottom of a Deep Downtrend? A High-Stakes Analysis for 2026 - Bitget
GCTK PE Ratio & Valuation, Is GCTK Overvalued - intellectia.ai
GlucoTrack Prepares FDA Submission for Implantable CBGM Trial - theglobeandmail.com
Glucotrack plans FDA submission for implantable glucose monitor By Investing.com - Investing.com Australia
Glucotrack to File for FDA Exemption Based on 2025 Milestones - Yahoo Finance
GCTK Stock Is Soaring Today — What Is Fueling The Surge? - Stocktwits
Glucotrack to Submit IDE Application to FDA in Early Q2 - citybiz
Glucotrack, Inc. (GCTK) Stock: Prepares FDA Submission as Clinical Data Shows Strong Accuracy - parameter.io
Glucotrack plans US trial of implantable glucose monitor this year - MedTech Dive
Microcap MedTech Moving on U.S. Clinical Milestone - theglobeandmail.com
GCTK stock GlucoTrack NASDAQ +29.80% on FDA IDE plan 27 Mar 2026: Earnings in focus - meyka.com
Latest Developments Propel GCTK Stock with Breakthrough Acquisitions - StocksToTrade
Why Is GlucoTrack Stock Soaring Friday?GlucoTrack (NASDAQ:GCTK) - Benzinga
GlucoTrack (GCTK) Surges 45% in Afternoon Trading—What's Fueling This Unusual Move? - Bitget
Glucotrack Inc Files Significant Ide with Fda for Us Clinical Trial in Early Second Quarter Based on Critical 2025 Milestones - marketscreener.com
Glucotrack plans FDA submission for implantable glucose monitor - Investing.com
Glucotrack to file IDE with FDA in Q2 2026 after successful human trials and new patents - tradingview.com
GCTK Stock Is Soaring Pre-Market Today — What Is Fueling The Surge? - Stocktwits
Glucotrack (NASDAQ: GCTK) advances implantable CBGM with IDE plan and new patents - Stock Titan
Glucotrack to file significant IDE with FDA for US clinical trial in early Q2 based on critical 2025 milestones - marketscreener.com
Glucotrack Plans IDE Submission to FDA in Early Q2 2026 for Non-Invasive Glucose Monitoring Clinical Trials - geneonline.com
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones - marketscreener.com
Brazil and Australia trials put Glucotrack on path to a U.S. diabetes study - Stock Titan
GlucoTrack Stock Gains As Data Backs FDA Filing Plans For Glucose Monitoring Tech - Sahm
Is GlucoTrack Inc. a stock for growth or value investorsWeekly Market Outlook & Weekly Top Stock Performers List - baoquankhu1.vn
Sentiment Review: What analysts say about GlucoTrack Inc stockOptions Play & Precise Entry and Exit Recommendations - baoquankhu1.vn
Growth Recap: Is GlucoTrack Inc backed by strong institutional buying2026 Closing Moves & Short-Term High Return Ideas - baoquankhu1.vn
GlucoTrack Shareholders Approve Capital Flexibility and Auditor Ratification - The Globe and Mail
GlucoTrack, Inc. 8-K SEC Filing: Company Details, Nasdaq Listing, and Key Disclosures (March 2026) - Minichart
Glucotrack shareholders approve stock issuances and auditor ratification - Investing.com
Glucotrack (GCTK) investors approve large stock and warrant issuances - Stock Titan
GCTK SEC FilingsGlucotrack 10-K, 10-Q, 8-K Forms - Stock Titan
Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit - Yahoo Finance
Chart Watch: Will GlucoTrack Inc benefit from geopolitical trendsMarket Movement Recap & Safe Capital Growth Plans - baoquankhu1.vn
GCTK Earnings History & Surprises | EPS & Revenue Results | GLUCOTRACK INC (NASDAQ:GCTK) - ChartMill
GCTK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GCTK Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Risk Recap: Should value investors consider GlucoTrack IncJuly 2025 Momentum & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Exit Recap: Can Oaktree Acquisition Corp III Life Sciences Equity Warrant benefit from deglobalization2025 Stock Rankings & Daily Growth Stock Investment Tips - baoquankhu1.vn
Armistice (GCTK) reports 9.99% stake — 101,075 shares disclosed - Stock Titan
Is GlucoTrack Inc. stock a buy before product launchesM&A Rumor & Technical Confirmation Alerts - mfd.ru
Glucotrack Inc Stock (GCTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):